Clinical use of tumor markers in childhood malignancies

Annals of Medicine

Volumn 34, Issue 5, 2002, Pages 316-323

  Lahdenne, Pekka ^a   Heikinheimo, Markku ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Cancer; Children; Oncofetal marker; Tumor marker

Indexed keywords

ALPHA FETOPROTEIN; CA 125 ANTIGEN; CA 19-9 ANTIGEN; CARBOHYDRATE ANTIGEN; CATECHOLAMINE; CHORIONIC GONADOTROPIN; MONOCLONAL ANTIBODY; NEURON SPECIFIC ENOLASE; TISSUE POLYPEPTIDE ANTIGEN; TUMOR MARKER;

ARTICLE; ATAXIA TELANGIECTASIA; CANCER DIAGNOSIS; CANCER THERAPY; CHILD; CHILDHOOD CANCER; GENE EXPRESSION; GERM CELL TUMOR; HUMAN; LIVER TUMOR; MALIGNANT TRANSFORMATION; NEUROBLASTOMA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; TYROSINEMIA; YOLK SAC TUMOR;

ALPHA-FETOPROTEINS; CA-125 ANTIGEN; CA-19-9 ANTIGEN; CATECHOLAMINES; CHILD; CHORIONIC GONADOTROPIN; CHROMOGRANIN A; CHROMOGRANINS; HUMANS; INFANT, NEWBORN; N-ACETYLNEURAMINIC ACID; NEOPLASMS; NEUROPEPTIDE Y; PEPTIDES; PHOSPHOPYRUVATE HYDRATASE; RADIOIMMUNODETECTION; TUMOR MARKERS, BIOLOGICAL;

EID: 0036434223     PISSN: 07853890     EISSN: None     Source Type: Journal    
DOI: 10.1080/078538902320772070     Document Type: Article

References (66)

1. Odelstad L, Pahlman S, Nilsson K, Larsson E, Lackgren G, Johansson KE, et al. Neuron-specific enolase in relation to differentiation in human neuroblastoma. Brain Res 1981; 224: 69-82.
2. Zeltzer PM, Marangos PJ, Parma AM, Sather H, Dalton A, Hammond D, et al. Raised neuron-specific enolase in serum of children with metastatic neuroblastoma. A report from the Children's Cancer Study Group. Lancet 1983; 2: 361-3.
3. Tapia FJ, Polak JM, Barbosa AJ, Bloom SR, Marangos PJ, Dermody C, et al. Neuron-specific enolase is produced by neuroendocrine tumours. Lancet 1981; 1: 808-11.
4. Tsuchida Y, Honna T, Iwanaka T, Saeki M, Taguchi N, Kaneko T, et al. Serial determination of serum neuron-specific enolase in patients with neuroblastoma and other pediatric tumors. J Pediatr Surg 1987; 22: 419-24.
5. Fizazi K, Farhat F, Theodore C, Rixe O, Le Cesne A, Comoy E, et al. Ca125 and neuron-specific enolase (NSE) as tumour markers for intra-abdominal desmoplastic small round-cell tumours. Br J Cancer 1997; 75: 76-8.
6. Österlundh G, Bjure J, Lannering B, Kjellmer I, Uvebrant P, Marky I. Regional cerebral blood flow and neuron-specific enolase in cerebrospinal fluid in children with acute lymphoblastic leukemia during induction treatment. J Pediatr Hematol Oncol 1999; 21: 378-83.
7. Royds JA, Collin RC, Timperley WR, Taylor CB, Lilleyman JS. Childhood leukemia: Cerebrospinal fluid enolase isoenzymes in central nervous system infiltration. Leukemia 1987; 1: 820-1.
8. Tuchman M, Auray-Blais C, Ramnaraine ML, Neglia J, Krivit W, Lemieux B. Determination of urinary homovanillic and vanillylmandelic acids from dried filter paper samples: Assessment of potential methods for neuroblastoma screening. Clin Biochem 1987; 20: 173-7.
9. Laug WE, Siegel SE, Shaw KN, Landing B, Babtista J, Gutenstein M. Initial urinary catecholamine metabolite concentrations and prognosis in neuroblastoma. Pediatrics 1978; 62: 77-83.
10. Hero B, Hunneman DH, Gahr M, Berthold F. Evaluation of catecholamine metabolites, mIBG scan, and bone marrow cytology as response markers in stage 4 neuroblastoma. Med Pediatr Oncol 2001; 36: 220-3.
11. Sawada T, Todo S, Fujita K, Iino S, Imashuku S, Kusunoki T. Mass screening of neuroblastoma in infancy. Am J Dis Child 1982; 136: 710-2.
12. Woods WG, Tuchman M, Robison LL, Bernstein M, Leclerc J-M, Brisson LC, et al. A population-based study of the usefulness of screening for neuroblastoma. Lancet 1996; 348: 1682-7.
13. Woods WG, Gao R-N, Shuster JJ, Robison LL, Bernstein M, Weitzman S, et al. Screening of infants and mortality due to neuroblastoma. N Engl J Med 2002; 346: 1041-6.
14. Schilling FH, Spix C, Berthold F, Erttmann R, Fehse N, Hero B et al. Neuroblastoma screening at one year of age. N Engl J Med 2002; 346: 1047-53.
15. O'Conner DT, Deftos LJ. Secretion of chromogranin A by peptide-producing endocrine neoplasms. N Engl J Med 1986; 314: 1145-51.
16. Cohen PS, Cooper MJ, Helman LJ, Thile CJ, Seeger RC, Israel MA. Neuropeptide Y expression in the developing adrenal gland and in childhood neuroblastoma tumors. Cancer Res 1990; 50: 6055-61.
17. Hsiao RJ, Seeger RC, Yu AL, O'Conner DT. Chromogranin A in children with neuroblastoma. Serum concentration parallels disease stage and predicts survival. J Clin Invest 1990; 85: 1555-9.
18. Rascher W, Kremens B, Wagner S, Feth F, Hunneman DH, Lang RE. Serial measurements of neuropeptide Y in plasma for monitoring neuroblastoma in children. J Pediatr 1993; 122: 914-6.
19. Kogner P, Ericsson A, Barbany G, Persson H, Theodorsson E, Bjork O. Neuropeptide Y (NPY) synthesis in lymphoblasts and increased plasma NPY in pediatric B-cell precursor leukemia. Blood 1992; 80: 1324-9.
20. Abelev GI. Alpha-fetoprotein in ontogenesis and its association with malignant tumors. Adv Cancer Res 1971; 14: 295-358.
21. Puck TT, Waldren CA, Jones C. Mammalian growth proteins. I. Growth stimulation of fetuin. Proc Natl Acad Sci USA 1968; 59: 192-9.
22. Aoyagi Y, Ikenaka T, Ichada F. Alpha-fetoprotein as a carrier-protein in plasma and its bilirubin-binding ability. Cancer Res 1979; 39: 3571-4.
23. Wajner M, Papiha SS, Wagstaff TI. Response of human peripheral blood lymphocytes in the presence of cord sera: Relationship of lymphocyte transformation with number of pregnancies and levels of alpha-fetoprotein. Clin Exp Immunol 1983; 52: 381-6.
24. Lahdenne P, Kuusela P, Siimes MA, Rönnholm KA, Salmenpera L, Heikinheimo M. Biphasic reduction and concanavalin A binding properties of serum alpha-fetoprotein in preterm and term infants. J Pediatr 1991; 118: 272-6.
25. Baranzelli MC, Kramar A, Bouffet E, Quintana E, Rubie H, Edan C, et al. Prognostic factors in children with localized malignant nonseminomatous germ cell tumors. J Clin Oncol 1999; 17: 1212-8.
26. Ishak KG. Primary hepatic tumors in childhood. In: Popper H, Schaffer F, eds. Progress in Liver Disease. New York, NY: Grune&Stratton; 1976: 636-67.
27. von Schweinitz D, Hecker H, Schmidt-von-Arndt G, Harms D. Prognostic factors and staging systems in childhood hepatoblastoma. Int J Cancer 1997; 74: 593-9.
28. Plaschkes J. Proceedings of an international research workshop on pediatric liver tumours. March 18-20, 1999, Bern, Switzerland. Into the year 2000. Med Pediatr Oncol 2001; 36: 380-2.
29. Goldsmith LA, Laberge C. Tyrosinaemia I. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic Basis of Inherited Disease. New York, NY: McGraw-Hill Co; 1989: 556-62.
30. Pitkänen ST, Salo MK, Heikinheimo M. Hereditary tyrosinaemia type I: From basics to progress in treatment. Ann Med 2000; 32: 530-8.
31. Vessella RL, Santrach MA, Bronson D, Smith CJ, Klicka MJ, Lange PH. Evaluation of AFP glycosylation heterogeneity in cancer patients with AFP-producing tumors. Int J Cancer 1984; 34: 309-14.
32. Perlin E, Engeler JE Jr, Edson M, Karp D, McIntire KR, Waldmann TA. The value of serial measurement of both human chorionic gonadotropin and alpha-fetoprotein for monitoring germinal cell tumors. Cancer 1976; 37: 215-9.
33. Jacobsen GK. Alpha-fetoprotein (AFP) and human chorionic gonadotropin (HCG) in testicular germ cell tumors. Acta Pathol Microbiol Scand 1983; 91A: 183-90.
34. Heikinheimo M, Rajantie J, Kuusela P, Kallio MJ, Siimes MA. Oncofetal markers CA 19-9, CA 125 and SP1 in healthy children and in children with malignancy. Br J Cancer 1990; 62: 865-7.
35. Gerl A, Lamerz R, Clemm C, Mann K, Hartenstein R, Wilmanns W. Does serum tumor marker half-life complement pretreatment risk stratification in metastatic nonseminomatous germ cell tumors? Clin Cancer Res 1996; 2: 1565-70.
36. Fosså SD, Stenning SP, Gerl A, Horwich A, Clark PI, Wilkinson PM, et al. Prognostic factors in patients progressing after cisplatin-based chemotherapy for malignant nonseminomatous germ cell tumours. Br J Cancer 1999; 80: 1392-9.
37. Trigo JM, Tabernero JM, Paz-Ares L, Garcia-Llano JL, Mora J, Lianes P, et al. Tumor markers at the time of recurrence in patients with germ cell tumors. Cancer 2000; 88: 162-8.
38. Van Tornout JM, Buckley JD, Quinn JJ, Feusner JH, Krailo MD, King DR, et al. Timing and magnitude of decline in alpha-fetoprotein levels in treated children with unresectable or metastatic hepatoblastoma are predictors of outcome: A report from the Children's Cancer Group. J Clin Oncol 1997; 15: 1190-7.
39. Walhof CM, Van Sonderen L, Voute PA, Delemarre JF. Half-life of alpba-fetoprotein in patients with a teratoma, endodermal sinus tumor, or hepatoblastoma. Pediatr Hematol Oncol 1988; 5: 217-27.
40. Kim EE, DeLand FH, Nelson MO, Bennett S, Simmons G, Alpert E, et al. Radioimmunodetection of cancer with radiolabeled antibodies to α-fetoprotein. Cancer Res 1980; 40: 3008-12.
41. Amato R, Kim EE, Prow D, Andropoulos D, Kasi LP. Radioimmunodetection of residual, recurrent or metastatic germ cell tumors using technetium-99 anti-(alpha-fetoprotein) Fab' fragment. J Cancer Res Clin Oncol 2000; 126: 161-7.
42. Fuchs J, Gratz KF, Habild G, Gielow P, von Schweinitz D, Baum RP. Immunoscintigraphy of xenotransplanted hepatoblastoma with iodine 131-labeled anti-alpha-fetoprotein monoclonal antibody. J Pediatr Surg 1999; 34: 1378-84.
43. Dresel S, Kirsch CM, Tatsch K, Zachoval R, Hahn K, Goldenberg DM. Detection of hepatocellular carcinoma with a new alpha-fetoprotein antibody imaging kit. J Clin Oncol 1997; 15: 2683-90.
44. Kairemo KJA, Lindahl H, Merenmies J, Föhr A, Nikkinen P, Karonen S-L, et al. Anti-AFP imaging is useful for staging hepatoblastoma. Transplantation 2002; 73: 1151-4.
45. Shouval D, Adler R, Wands J, Hurwitz E, Isselbacher K, Sela M. Doxorubicin conjugates of monoclonal antibodies to hepatoma-associated antigens. Proc Natl Acad Sci USA 1988; 8: 8276-80.
46. Konno H, Suzuki H, Tadakuma T, Kumai K, Yasuda T, Kubota T, et al. Antitumor effect of adriamycin entrapped in liposomes conjugated with anti-human alpha-fetoprotein monoclonal antibody. Cancer Res 1987; 47: 4471-7.
47. Koprowski H, Steplewski Z, Mitchell K, Herlyn M, Herlyn D, Fuhrer P. Colorectal carcinoma antigens detected by hybridoma antibodies. Somatic Cell Genet 1979; 5: 957-71.
48. Haglund C, Roberts PJ, Jalanko H, Kuusela P. Tumour markers CA 19-9 and CA 50 in digestive tract malignancies. Scand J Gastroenterol 1992; 27: 169-74.
49. Nishida K, Miyagawa H, Yoshikawa T, Kondo M. Concentration and localization of carbohydrate antigen 19-9 in tissues of pancreatic cancer. Oncology 1988; 45: 166-71.
50. Lahdenne P, Pitkänen S, Rajantie J, Kuusela P, Siimes MA, Lanning M, et al. Tumor markers CA 125 and CA 19-9 in cord blood and during infancy: Developmental changes and use in pediatric germ cell tumors. Pediatr Res 1995; 38: 797-801.
51. Angel CA, Pratt CB, Rao BN, Schell MJ, Parham DM, Lobe TE, et al. Carcinoembryonic antigen and carbohydrate 19-9 antigen as markers for colorectal carcinoma in children and adolescents. Cancer 1992; 69: 1487-91.
52. Bast RC Jr, Klug TL, St John E, Jenison E, Niloff JM, Lazarus H, et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 1983; 309: 883-7.
53. Bast RC Jr. Perspectives on the future of cancer markers. Clin Chem 1993; 39: 2444-51.
54. Lopez JB, Balasegaram M, Thambyrajah V. Serum CA 125 as a marker of hepatocellular carcinoma. Int J Biol Markers 1996; 11: 178-82.
55. Pitkänen S, Salo MK, Kuusela P, Holmberg C, Simell O, Heikinheimo M. Serum levels of oncofetal markers CA 125, CA 19-9, and alpha-fetoprotein in children with hereditary tyrosinaemia type I. Pediatr Res 1994; 35: 205-8.
56. Lazzarino M, Orlandi E, Klersy C, Astori C, Brusamolino E, Corso A, et al. Serum CA 125 is of clinical value in the staging and follow-up of patients with non-Hodgkin's lymphoma: Correlation with tumor parameters and disease activity. Cancer 1998; 82: 576-82.
57. Kutluk T, Varan A, Erbas B, Buyukpamukcu M. Serum CA 125 levels in children with non-Hodgkin's lymphoma. Pediatr Hematol Oncol 1999; 16: 311-9.
58. Petäjä J, Pitkänen S, Vettenranta K, Fasth A, Heikinheimo M. Serum tumor marker CA 125 is an early and sensitive indicator of veno-occlusive disease in children undergoing bone marrow transplantation. Clin Cancer Res 2000; 6: 531-5.
59. Rydlander L, Ziegler E, Bergman T, Schoberl E, Steiner G, Bergman AC, et al. Molecular characterization of a tissuepolypeptide-specific-antigen epitope and its relationship to human cytokeratin 18. Eur J Biochem 1996; 241: 309-14.
60. Rebhandl W, Rami B, Turnbull J, Felberbauer FX, Paya K, Bancher-Todesca D, et al. Diagnostic value of tissue polypeptide-specific antigen (TPS) in neuroblastoma and Wilms' tumour. Br J Cancer 1998; 78: 1503-6.
61. Rebhandl W, Paya K, Felberbauer FX, Fuchs R, Henkel J, Bieglmayer C, et al. Tissue polypeptide-specific antigen (TPS) in pediatric malignancies. Anticancer Res 1997; 17: 2865-8.
62. Yogeeswaran G. Cell surface glycolipids and glycoproteins in malignant transformation. Adv Cancer Res 1983; 38: 289-350.
63. Seider A, Graf N, Sitzmann FC. Value of serum sialic acid determination in children. Padiatr Padol 1992; 27: 43-6.
64. Romppanen J, Petäjä J, Heikinheimo M, Mononen I. Total and lipid-bound serum sialic acid in children with malignancy or infections. Anticancer Res 1998; 18: 2793-7.
65. O'Kennedy R, Berns G, Moran E, Smyth H, Carroll K, Thornes RD, et al. A critical analysis of the use of sialic acid determination in the diagnosis of malignancy. Cancer Lett 1991; 58: 91-100.
66. Asami T, Tanaka A, Gunji T, Sakai K, Asami K. Elevation of cerebrospinal fluid sialic acid concentration in children with central nervous system leukemia. Acta Paediatr Stand 1987; 76: 260-5.